tirzepatide cardiovascular outcome 💉 In a large real-world study, was associated with a lower incidence of major outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart SURPASS-CVOT Published: Large Trial Confirms

The 2% to 3% efficacy gap between orforglipron and Wegovy represents 5 to 7 fewer pounds lost for a 200-pound person

Were calling it out here because adequate protein intake coupled with resistance training is the most effective way to preserve lean muscle mass while in a calorie deficit, which is almost guaranteed when combining semaglutide with intermittent fasting

When semaglutide is prescribed for weight management, coverage becomes much less predictableeven though Wegovy is FDA-approved for that purpose

The before and after photos circulating on social media and clinic websites represent anecdotal evidence at best